179 related articles for article (PubMed ID: 31990147)
1. Lobetyolin induces apoptosis of colon cancer cells by inhibiting glutamine metabolism.
He W; Tao W; Zhang F; Jie Q; He Y; Zhu W; Tan J; Shen W; Li L; Yang Y; Cheng H; Sun D
J Cell Mol Med; 2020 Mar; 24(6):3359-3369. PubMed ID: 31990147
[TBL] [Abstract][Full Text] [Related]
2. Lobetyolin inhibits the proliferation of breast cancer cells
Chen Y; Tian Y; Jin G; Cui Z; Guo W; Zhang X; Liu X
Hum Exp Toxicol; 2021 Dec; 40(12):2074-2086. PubMed ID: 34075790
[TBL] [Abstract][Full Text] [Related]
3. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
[TBL] [Abstract][Full Text] [Related]
4. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
5. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
7. Lobetyolin inhibits cell proliferation and induces cell apoptosis by downregulating ASCT2 in gastric cancer.
Cheng L; Zhai H; Du J; Zhang G; Shi G
Cytotechnology; 2023 Oct; 75(5):435-448. PubMed ID: 37655270
[TBL] [Abstract][Full Text] [Related]
8. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
Wang W; Pan H; Ren F; Chen H; Ren P
Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
[TBL] [Abstract][Full Text] [Related]
9. Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress.
Zhou G; Qin M; Zhang X; Yang J; Yu H
Gastroenterol Hepatol; 2021 Jan; 44(1):1-12. PubMed ID: 33039171
[TBL] [Abstract][Full Text] [Related]
10. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
11. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
12. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
13. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
15. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.
Fuchs BC; Perez JC; Suetterlin JE; Chaudhry SB; Bode BP
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G467-78. PubMed ID: 14563674
[TBL] [Abstract][Full Text] [Related]
16. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
17. MiR-125b blocks Bax/Cytochrome C/Caspase-3 apoptotic signaling pathway in rat models of cerebral ischemia-reperfusion injury by targeting p53.
Xie YL; Zhang B; Jing L
Neurol Res; 2018 Oct; 40(10):828-837. PubMed ID: 29956588
[TBL] [Abstract][Full Text] [Related]
18. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
19. GSIV serine/threonine kinase can induce apoptotic cell death via p53 and pro-apoptotic gene Bax upregulation in fish cells.
Reshi L; Wu HC; Wu JL; Wang HV; Hong JR
Apoptosis; 2016 Apr; 21(4):443-58. PubMed ID: 26833308
[TBL] [Abstract][Full Text] [Related]
20. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]